
*Investigation of Chinese Herbal Medicine
in treatment of Metabolic Syndrome*

John Shim

A thesis submitted for the degree of
Master of Science



Department of Medical and Molecular Biosciences
Faculty of Science
The University of Technology, Sydney, Australia
2008

Declaration

I declare that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text. I also declare that this thesis has been written by me. Any help I received in my research and preparation of this thesis has been acknowledged.

Signature of Student

Production Note:
Signature removed prior to publication.

John Shim

2008

Acknowledgements

I am very grateful to my supervisor, Associate Professor Xianqin Qu, without whom I could not have successfully completed my Master's degree by research thesis. I sincerely thank her for all the support and supervision she has provided me throughout the course of this degree.

I would like to express my appreciation to Yi Tan for all the kind support and assistance she has given me during the course of my study. Her help in the technical aspects of experiments and analyses of results have been vital to development of this thesis. I would also like to thank the following postgraduate students: Jane Kim, Christine Kim, Mohammad Kamal, Sarwut Al-Qassab, and Binhai Ren for their continuous help and encouragements. I would like to thank the following people: Prof. Bill Booth for the provision of care and management of the animals used in my experiment; Michael Johnson, Phillip Lawrence and Puthayalai Treerat for providing me with the equipment I needed in my experiment; and Sue Felix for proof reading my thesis.

Finally, I would like to thank my family members, my father, mother and brother for their love and continuous support throughout my study period. Their care and support for me have been essential in difficult times.

Communications

Parts of this thesis have already been presented in abstract form at a scientific meeting:

Shim, J. H. B., Kim, C. H. J., Tan, Y., Kim, J. J. Y. & Qu, X. (2008) Investigation of Chinese Herbal Medicine in Treatment of Metabolic Syndrome. Annual Scientific Meeting of Australian Diabetes Society (ADS) Melbourne, Australia.

Kim, J. J. Y., Tan, Y., Shim, J. H. B., Kim, C. H. J. & Qu, X. (2008) The Effects and Mechanisms of Notoginsenosides on Glucose and Lipid Metabolism in 3T3-L1 Cells. Annual Scientific Meeting of Australian Diabetes Society (ADS) Melbourne, Australia.

Table of Contents

Declaration	i
Acknowledgements	ii
Communications	iii
Table of Contents	iv
List of Tables and Figures	viii
List of Abbreviations	x
Abstract	xi

Chapter 1 General introduction

1.1. Metabolic syndrome.....	1
1.1.1. Definition of MetS.....	1
1.1.2. Causative factors of MetS.....	3
1.1.1.1 Environmental factors.....	3
1.1.1.2 Genetic susceptibility to MetS.....	3
1.1.2 Prevalence of MetS.....	4
1.1.3 T2DM in relation to MetS.....	5
1.2 Mechanism of insulin resistance in the pathogenesis of MetS.....	6
1.2.1 Physiological functions of insulin.....	6
1.2.2 Definition and significance of insulin resistance.....	6
1.2.3 Impairment of insulin signalling pathways.....	7
1.3 Mechanism of central obesity in the pathogenesis of MetS.....	10
1.3.1 Definition and significance of central obesity.....	10
1.3.2 Possible causes of central obesity.....	10
1.3.3 Central obesity, FFAs and insulin resistance.....	12
1.4 Mechanism of pro-inflammatory and pro-thrombotic states in the pathogenesis of MetS.....	14
1.4.1 Pro-inflammatory and pro-thrombotic adipocytokines.....	15

1.5	Additional metabolic and haemodynamic abnormalities of MetS.....	17
1.5.1	Dyslipidaemia.....	17
1.5.2	Hypertension.....	18
1.6	Animal models of MetS.....	19
1.6.1	Zucker fatty and Zucker fatty diabetic rats.....	19
1.6.2	ob/ob mice.....	20
1.6.3	Dietary factor-induced model.....	20
1.7	Therapeutic interventions for MetS.....	22
1.7.1	Lifestyle therapies.....	22
1.7.2	Pharmacotherapy.....	23
1.7.2.1	Drugs for T2DM.....	23
1.7.2.2	Drugs for obesity.....	24
1.7.2.3	Drugs for dyslipidaemia.....	25
1.7.2.4	Drugs for hypertension.....	25
1.7.2.5	Other drugs.....	26
1.8	Discovery and development of new drugs	27
1.8.1	Adverse effects of current therapies.....	27
1.8.2	Chinese herbal medicine.....	28
1.9	Aims of this thesis.....	29

Chapter 2 Materials and methods

2.1	Experimental animals and materials.....	30
2.1.1	Animals.....	30
2.1.2	Ethics approval.....	30
2.1.3	High fat diet.....	30
2.1.4	Collection of blood and tissue samples.....	31
2.1.5	Chemicals.....	31

2.2 In vivo measurements.....	32
2.2.1 Body weight and food intake.....	32
2.2.2 Blood glucose test.....	32
2.2.3 Intra-peritoneal glucose and insulin tolerance tests.....	33
2.3 Laboratory assay of serum samples.....	33
2.3.1 Triglyceride concentration.....	33
2.3.2 Non-esterified fatty acid concentration.....	34
2.3.3 Cholesterol concentration.....	35
2.3.4 Insulin concentration.....	36
2.4 Analyses of lipids in liver tissues.....	37
2.4.1 Hepatic triglyceride concentration.....	37
2.4.2 Histological assessment of total lipid contents in liver.....	38
2.5 Statistical analysis.....	39

Chapter 3 Investigation of Sugarid in mice models of type 2 diabetes and metabolic syndrome

3.1 Introduction.....	41
3.2 Research plan and methods.....	42
3.3 Results.....	45
3.3.1 Induction of MetS and T2DM in mice.....	45
3.3.2 Effects of Sugarid on the body and visceral fat weights.....	47
3.3.3 Effects of Sugarid on glucose metabolism.....	49
3.3.4 Effects of Sugarid on insulin sensitivity.....	52
3.3.5 Effects of Sugarid on lipid metabolism.....	54
3.4 Discussion.....	57

Chapter 4 Investigation of SK0504 in mice model of metabolic syndrome

4.1 Introduction.....	60
4.2 Research plan and methods.....	61
4.3 Results.....	63

4.3.1 Effects of SK0504 on the body and visceral fat weights.....	63
4.3.2 Effects of SK0504 on glucose metabolism.....	65
4.3.3 Effects of SK0504 on insulin sensitivity.....	66
4.3.4 Effects of SK0504 on lipid metabolism.....	69
4.4 Discussion.....	73
Chapter 5 Conclusions and future directions	
5.1 Summary and conclusions.....	76
5.2 Future directions.....	77
References.....	79
Appendix.....	91

List of Tables & Figures

Tables

1.1	Definition of MetS according to ATP III and IDF.....	2
1.2	Three ranges of hyperglycaemia.....	6
1.3	Recommendations for weight loss and diet.....	23

Figures

1.1	Altered insulin signaling pathways in insulin resistance.....	8
1.2	Brief outline of molecular steps in glycogen synthesis.....	9
1.3	Pathogenesis of central obesity in association to adiposopathy.....	12
3.1	The body weights of mice fed with chow diet or HFD.....	46
3.2	The blood glucose levels of mice with MetS or T2DM.....	46
3.3	Effects of Sugarid on the body and visceral fat weights.....	48
3.4	Daily food intake of the mice during treatment.....	49
3.5	Effects of Sugarid on the blood glucose levels.....	50
3.6	Effects of Sugarid on intra-peritoneal glucose tolerance.....	51
3.7	AUC following intra-peritoneal glucose tolerance test.....	52
3.8	Effects of Sugarid on intra-peritoneal insulin tolerance.....	53
3.9	Effects of Sugarid on the serum lipid levels.....	55
3.10	Effects of Sugarid on the liver triglyceride levels.....	56
3.11	Histological assessment of the livers from mice.....	56
4.1	Effects of SK0504 on the body weights	64
4.2	Effects of SK0504 on the visceral fat weights.....	64
4.3	Effects of SK0504 on the blood glucose levels.....	65

4.4	Effects of SK0504 on intra-peritoneal glucose tolerance.....	67
4.5	Effects of SK0504 on intra-peritoneal insulin tolerance.....	68
4.6	Effects of SK0504 on the serum insulin levels.....	69
4.7	Effects of SK0504 on the serum lipid levels.....	71
4.8	Effects of SK0504 on the liver triglyceride levels.....	72
4.9	Histological assessments of the livers from mice.....	72

List of Abbreviations

ASCVD	Atherosclerotic cardiovascular disease
AUC	Area under curve
FFA	Free fatty acids
GLUT-4	Glucose transporter-4
HDL-C	High density lipoprotein cholesterol
HFD	High fat diet
IDF	International Diabetes Federation
i.p. GTT	Intra-peritoneal glucose tolerance test
i.p. ITT	Intra-peritoneal insulin tolerance test
LDL-C	Low density lipoprotein cholesterol
MetS	Metabolic syndrome
NCEP	National Cholesterol Education Program
NEFA	Non-esterified fatty acids
PI(3)k	Phosphatidylinositol 3-kinase
PPAR	Peroxisome proliferator-activated receptor
RAAS	Renin-angiotensin-aldosterone-system
SEM	Standard error of mean
STZ	Streptozotocin
T2DM	Type 2 diabetes mellitus
TNF- α	Tumour necrosis factor- α
TZD	Thiazolidinedione
VLDL-C	Very low density lipoprotein cholesterol
WHO	World Health Organisation

Abstract

Metabolic syndrome (MetS) is a clustering of atherosclerotic cardiovascular disease (ASCVD) risk factors including central obesity, insulin resistance, dyslipidaemia, hypertension, and pro-inflammatory and pro-thrombotic states. It is also a precursor of type 2 diabetes mellitus (T2DM). Research continues to uncover the mechanical links of the pathogenesis of MetS as well as to discover new drugs to target the multiple metabolic and haemodynamic abnormalities of MetS. The focus of this thesis is on the investigation of two Chinese herbal medicines, Sugarid and SK0504, in the treatment of MetS and T2DM induced in C57BL/6J mice by high fat diet (HFD) feeding with or without streptozotocin (STZ) injection.

The results described in Chapter 3 show that T2DM was induced in mice fed HFD when their blood glucose levels rose after the STZ injection. Treatment with a Chinese herbal product, Sugarid did not show any significant improvements of body and visceral fat weights, glucose metabolism, insulin sensitivity, and serum and liver lipid parameters in either MetS and T2DM models of mice. Therefore, the findings from this study do not support the notion of Sugarid being a potential drug in treatment of MetS and T2DM.

The purpose of Chapter 4 is to investigate the effects and mechanisms of a new herbal formula, SK0504 in HFD fed mice. Treatment with SK0504 showed significant improvements of visceral fat weight, insulin sensitivity and some biochemical parameters. The findings of this study showed potential beneficial effects of SK0504 on MetS by its ability to target central obesity, insulin resistance and hyperlipidaemia. However, the hypothesised effects of SK0504 in targeting the multiple metabolic

abnormalities of MetS were not obtained. The last chapter outlines possible avenues for further research in order to confirm any implications of the experimental findings reported in this thesis.